This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 14-17, 2022
San Diego Convention CenterSan Diego, California

Tom A. Brieva, Ph.D.
Vice President, Process Development at Tmunity Therapeutics


Tom Brieva has played a process development role in the commercialization of cell-based pharmaceuticals since joining industry in 2004, first at Celgene/BMS and now at Tmunity Therapeutics.  His accomplishments include the development of robust, reproducible, economically viable cell manufacturing processes and the implementation of them to the in-house generation of GMP grade product from clinical through commercial stages.  Tom has led process development for a variety of autologous and expanded allogeneic cell-based products that originated either internally or from external industrial or academic partners.  These products range from expanded umbilical cord blood stem cells to placenta-derived MSC-like cells to CAR T cells as well as gene delivery vectors.

Agenda Sessions

  • Suitable Manufacturing & Analytical Approaches for Wide Diversity of Cell and Gene Therapies